10.1016/j.jacc.2018.11.054 12
Birth Defects Res (2017) 109(16):124356
Off-label prescribing is based on solid clinical evidence
A similar trend was observed in REWIND, where sustained benefits emerged with extended treatment exposure, suggesting that younger people, by virtue of prolonged therapy duration, may accrue a greater cumulative benefit from GLP-1 RAs [41], potentially explaining the more marked death reduction observed in this subgroup within our study
Younger adults were the most anxious about injections 18-24 year olds were the most likely age group to say they were concerned before starting injections, with 76.47% reporting concern
GLP-1 e o Ozempic O Ozempic (semaglutida) um medicamento que imita a ao do GLP-1, mas com um tempo de ao muito mais longo